 |
|
TUESDAY, 9 SEPTEMBER 2008 |
|
|
7:00AM- 8:45AM |
ISPOR ASIA-PACIFIC MEDICAL DEVICE & DIAGNOSTICS COUNCIL FORUM
(Continental Breakfast is provided) Flamingo |
| |
With the rapid development of health technology, health technology assessment more and more plays an important role in field of medical device & diagnostics to meet multiple health system needs. This forum will provide a platform for the professionals from government, academia and industry in the Asia-Pacific region to highlight current policies and innovations, discuss issues and challenges, and provide the range of evidence-based tools and resources to help make better informed decisions.
Moderator:
Madeleine R. Valera MD, MScIH (Heidelberg), 2008-2010 Vice-Chair of ISPOR Asia-Pacific Medical Device & Diagnostic Council, & Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, Pasig City, Philippines
Biographical Information |
|
 |
| M. Valera |
|
Health Technology Assessment and Management
Jie Chen PhD, 2008-2010 Chair of ISPOR Asia-Pacific Medical Device & Diagnostic Council & Director, Key Lab of HTA, Ministry of Health, and Professor, School of Public Health, Fudan University, Shanghai, China
Biographical Information |
|
 |
| J. Chen |
|
| |
|
|
Evidence-based Health Policies for Medical Devices and Diagnostics in Asia
Kai Hong Phua AB, SM, PhD, Professor of Health Policy & Management, Lee Kuan Yew School of Public Policy, National University of Singapore, Singapore, Singapore
Biographical Information |
|
 |
| K. Phua |
|
| |
|
|
Innovation in Medical Technologies: Value and Incentives
Ashoke Bhattacharjya PhD, Executive Director, Health Economics and Policy, Johnson & Johnson Medical, Asia Pacific, New Delhi, India
Biographical Information |
|
 |
| A.Bhattacharjya |
|
| |
|
|
HTA and Accelerated Access of New Medical Technology to Patients
Kathy Cargill MSc, MRPharmS, Senior Director, Reimbursement and Health Economics, Medtronic International, Tolochenaz, Switzerland
Biographical Information |
|
 |
| K. Cargill |
|
| |
|
|
Health Technology Assessment in South Korea
Seong-Hi Park PhD, Director, HTA Team, Health Insurance and Review Assessment & Service, Seoul, South Korea
Biographical Information |
|
 |
| S. Park |
|
|
|
8:00AM-9:00AM |
EXHIBIT & POSTER PRESENTATION
VIEWING |
|
|
|
9:00AM-9:15AM |
WELCOME Convention Hall DE |
|
 Chris L. Pashos PhD, 2008-2009 ISPOR President, and Vice President & Executive Director, HERQuLES Health Economic Research and Quality of Life Evaluation Services Abt Bio-Pharma Solutions, Inc., Lexington, MA, USAs
Biographical Information
 Bong-Min Yang PhD, Program Chair, and Professor, School of Public Health, Seoul National University, Seoul, South Korea
Biographical Information
|
|
9:15AM-10:45AM |
THIRD PLENARY SESSION Convention Hall DE |
|
DEVELOPING AND IMPLEMENTING PHARMACOECONOMIC
GUIDELINES:
Lessons Learned from Australia and South Korea
Lessons Learned from Australia and South Korea This session will give an overview of experience and lessons learned in developing and implementing pharmacoeconomic guidelines in Australia, the leading country that introduced pharmacoeconomic guidelines to the
world. It will also focus on South Korea, where pharmacoeconomic guidelines were issued in 2006, and the guidelines have been officially implemented since 2007. Practical issues in implementing guidelines in South Korea will also be address.
Moderator:
Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea
Biographical Information |
|
| B. Yang |
|
Speakers:
Rosalie Viney PhD, Associate Professor, and Deputy Director, Centre for Health Economics Research & Evaluation, Sydney, Australia
Biographical Information
Eun-Young Bae PhD, Assistant Professor, College of Health Sciences, Sanji University, Wonju, South Korea
Biographical Information |
 |
 |
| R. Viney |
E. Bae |
|
|
|
10:45AM-11:10AM |
BREAK, EXHIBITS & POSTER
PRESENTATIONS VIEWING |
|
|
11:00AM-12:00PM |
PODIUM PRESENTATIONS-SESSION II |
|
Cost-Effectiveness Studies White Heron |
| Moderator: Wen Chen PhD, Professor and Associate Dean, School of Public Health, Fudan University, Shanghai, China |
| |
|
| CE1: |
COST-EFFECTIVENESS ANALYSES OF CHRONIC HEPATITIS B AND C MANAGEMENT IN TAIWAN – BASED ON REAL WORLD DATA FROM THE PILOT HEPATITIS REIMBURSEMENT PROGRAM |
| |
Pwu RF1, Chen CL2, Kao JH2, Lai MY2
1Taipei Medical University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan |
| |
|
| CE2: |
A COST-EFFECTIVENESS ANALYSIS FOR CHRONIC HEPATITIS B VIRUS WITH CIRRHOSIS BY DISCRETE EVENT SIMULATION |
| |
Luh H1, Phua S2
1National Chengchi University, Taipei, Taiwan, 2Agenix Limited, Singapore, Singapore |
| |
|
| CE3: |
COST-EFFECTIVENESS OF SMOKING CESSATION IN AUSTRALIA WITH VARENICLINE, A NOVEL PHARMACOTHERAPY. |
| |
Brown A1, Webb K2, Kim H3, Liew D4
1Pfizer Australia Pty Limited, West Ryde, NSW, Australia, 2Pfizer Inc, Tadworth, Surrey, United Kingdom, 3Pfizer Inc, Sydney, NSW, Australia, 4University of Melbourne, Melbourne, Victoria, Australia |
| |
|
| CE4: |
THE LONG-TERM ECONOMIC IMPACT OF CERVICAL CANCER VACCINATION IN TAIWAN |
| |
You SL1, Tang CH2, Ferko N3, Debicki D3, Chen YC4, Chen CJ1
1Genomics Research Center, Academia Sinica, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3i3 Innovus Research Inc, Burlington, ON, Canada, 4GlaxoSmithKline, Taipei, Taiwan |
| |
|
| Cost Studies Skylark |
| Moderator: Ahmad Fuad Afdhal PhD, Chief Executive Officer, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia |
| |
|
| CS1: |
COST ANALYSIS OF TREATING ACUTE MYOCARDIAL INFARCTION IN INDIA |
| |
Lertpitakpong C1, Neramitpitagkul P1, Thavorncharoensap M1, Chaikledkaew U2, Teerawattananon Y1
1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand |
| |
|
| CS2: |
ANALYSIS OF SOCIOECONOMIC COST OF SMOKING IN KOREA |
| |
Kim CH1, Song HR2, Park S3, Ko S4
1Department of Healthcare Policy and Management/Smoking Cessation Clinic of Seoul Paik Hospital, Seoul, South Korea, 2Inje University, Seoul, South Korea, 3Yonsei University, Seoul, South Korea, 4Pfizer Korea, Seoul, South Korea |
| |
|
| CS3: |
COST OF SUSPECTED INVASIVE PNEUMOCOCCAL DISEASES IN VIETNAMESE CHILDREN |
| |
Riewpaiboon A1, Anh DD2, Tho LH3, Kim SA4, Kilgore PE4
1Faculty of Pharmacy Mahidol University, Ratchathevi, Bangkok, Thailand, 2National Institute of Hygiene and Epidemiology, Hanoi, Hanoi, Vietnam, 3Khanh Hoa Provincial Public Health Service, Nha Trang, Khanh Hoa, Vietnam, 4International Vaccine Institute, Kwanak, Seoul, South Korea |
| |
|
| CS4: |
THE IMPACT OF A HIGHER PD UTILIZATION RATE FOR DIALYSIS TREATMENT ON KOREA'S GOVERNMENT EXPENDITURES |
| |
Chen L1, Bang J2, Walker D3
1Baxter Healthcare Asia Pacific, Shanghai, Shanghai, China, 2Baxter Healthcare Korea, Seoul, Seoul, South Korea, 3Baxter Healthcare US, Chicago, IL, USA |
| |
|
Health Policy Flamingo |
| Moderator: Syed Mohamed Aljunid MD, MSc, PhD, FAMM, Professor of Health Economics & Consultant Public Health Medicine, Senior Research Fellow, United Nations University-International Institute of Global Health (UNU-IIGH), HUKM Complex, and Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia |
| |
|
| HP1: |
THE IMPLICATIONS OF BENEFIT PACKAGE DESIGN: THE IMPACT ON POOR THAI HOUSEHOLDS OF EXCLUDING RENAL REPLACEMENT THERAPY |
| |
IPrakongsai P1, Tangcharoensathien V2
1International Health Policy Program (IHPP), Nonthaburi, Nonthaburi, Thailand, 2International Health Policy Program - Thailand, Nonthaburi, Thailand |
| |
|
| HP2: |
SURVEY ON THE CURRENT HUMAN CAPACITY AND FUTURE NEEDS IN ECONOMIC EVALUATION IN THAILAND |
| |
Chaikledkaew U1, Lertpitakpong C2, Orrawattanakul Y2, Pimsawan N2, Kulpeng W2, Thavorncharoensap M2, Teerawattananon Y2, Tangcharoensathien V3
1Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand, 2Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 3International Health Policy Program - Thailand, Nonthaburi, Thailand |
| |
|
| HP3: |
TREATMENT PATTERN AND OUTCOME ASSESSMENT OF ASTHMATIC PATIENTS ADMITTED TO ACCIDENT & EMERGENCY DEPARTMENT (ED) IN A TERTIARY TEACHING HOSPITAL |
| |
Hussain SH1, Wong SW1, Ramli MN2, Raja Mohamed AA2
1University of Malaya, Kuala Lumpur, Federal Territory, Malaysia, 2University Malaya Medical Centre, Kuala Lumpur, Federal Territory, Malaysia |
| |
|
| HP4: |
A STUDY OF MEDICINE PRICES, AVAILABILITY AND AFFORDABILITY IN SHANGHAI, CHINA |
| |
Ye L1, Hu S2
1School of Public Health, Fudan University, Shanghai, China, 2Fudan University, Shanghai, China |
| |
|
| Research on Methods Swan |
| Moderator: Madeleine R. Valera MD, MScIH (Heidelberg), Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, CityState Center, Pasig City, Philippines |
| |
|
| ME1: |
A NEW APPROACH FOR MONITORING DRUG PRICE BEHAVIORS: MISCELLANEOUS ACQUISITION CAPABILITY (MAC) |
| |
Udom-aksorn S1, Sakulbumrungsil R2
1Prince of Songkla University, Hatyai, Songkhla, Thailand, 2Chulalongkorn University, Patumwan, Bangkok, Thailand |
| |
|
| ME2: |
THE QUANTITY COST-EFFECTIVENESS ACCEPTABILITY CURVE BASED ON THE FULL INFORMATION OF INDIVIDUAL NET BENEFIT IN HEALTH-RELATED ECONOMIC EVALUATION |
| |
Kim S, Suh J, Kim KH, Kim JS, Kim HK
Novartis, Seoul, South Korea |
| |
|
| ME3: |
VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSE THEORY – APPLICATION OF KERNEL REGRESSION |
| |
Lin HW1, Pickard AS2, Karabatsos G3, Mahady GB2, Crawford SY2, Popovich NG2
1China Medical University, Taichung, Taiwan, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3College of Education, University of Illinois at Chicago, Chicago, IL, USA |
| |
|
| ME4: |
FACTORS AFFECTING WILLINGNESS-TO-PAY FOR TREATMENT OF BLINDNESS IN THAI POPULATION |
| |
Kulpeng W, Natanant S, Thavorncharoensap M, Teerawattananon Y
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand |
| |
|
| Patient-Reported Outcomes Studies Crane |
| Moderator: Sang-Cheol Bae MD, PhD, MPH, Professor and Director, The Hospital for Rheumatic Diseases, and Head, Section for Clinical Epidemiology and Economics, Hanyang University, Seoul, South Korea |
| |
|
| PR1: |
HEALTH RELATED UTILITY OF AUSTRALIAN RHEUMATOID ARTHRITIS PATIENTS CORRELATES WITH HAQ BUT NOT TOTAL TENDER AND SWOLLEN JOINT COUNTS |
| |
Norris S1, Harvey C1, Elliott L1, Standfield L1, Riordan J2, Hall S3, Day R4, Nash P5, Thiru K6, Robertson J6, Palmer T6 |
| |
1Health Technology Analysts Pty Ltd, Sydney, Australia, 2Illawara Rheumatology, Woollongong, Australia, 3Cabrini Medical Centre, Malvern, Australia, 4St Vincents Clinical Trial Centre, Sydney, Australia, 5Sixth Avenue Specialist Centre, Cotton Tree, Australia, 6Wyeth Australia, Sydney, Australia |
| |
|
| PR2: |
HEALTH RELATED QUALITY OF LIFE AND ITS ASSOCIATED FACTORS IN PATIENTS WITH TYPE 2 DIABETES IN SOUTH KOREA |
| |
Jo MW1, Lee WJ2, Noh JH3, Song KH4, Choi YJ5 |
| |
1Dongguk University, Gyeongju, Gyeongbuk, South Korea, 2Inje University Sanggye Paik Hospital, Seoul, South Korea, 3Inje University Ilsan Paik Hospital, Ilsan, Gyeonggi-Do, South Korea, 4Kunkuk University Hospital, Seoul, South Korea, 5Sanofi-Aventis Korea, Seoul, South Korea |
| |
|
| PR3: |
DOES COMBINING AMLODIPINE AND ATORVASTATIN INTO A SINGLE PILL IMPROVE ADHERENCE IN THE TARGET POPULATION? COMBINED EVIDENCE FROM TWO US RETROSPECTIVE DATABASE STUDIES |
| |
Earle KL, Delahoy PJ, Dabin B, Brown AJ
Pfizer Australia Pty Ltd, West Ryde, NSW, Australia |
| |
|
| PR4: |
DETERMINATION OF THE LONGITUDINAL VALIDITY AND MINIMALLY IMPORTANT DIFFERENCE OF THE 8-ITEM PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-8) |
<
|
Zhao YJ1, Tan LC2, Lau PN2, Au WL2, Li SC3, Luo N4 |
|
1National University of Singapore, Singapore, Singapore, Singapore, 2National Neuroscience Institute, Singapore, Singapore, 3University of Newcastle, Callaghan, NSW, Australia, 4National University of Singapore, Singapore, Singapore |
|
|
|
|
12:00PM-1:30PM |
LUNCH, EXHIBITS & POSTER PRESENTATIONS VIEWING Grand Ballroom |
|
|
12:30PM-1:30PM |
EDUCATIONAL SYMPOSIUM (Sponsored by IMS Health) Convention Hall DE |
|
Evolving trends in HTA: Comparing the evidence
This symposium will compare some of the key markets in terms of their HTA structure, the recent activity of the HTA decision making body, the kinds of decisions that have been made, and the likely focus and impact on future health care costs and outcomes. A framework for comparing "HTA effectiveness" will be put forward and at 2 or more countries will be compared using that framework. Implications for medical innovation, health care quality and cost management will be discussed in light of this analysis.
|
|
1:30PM-2:30PM |
|
|
ECONOMIC OUTCOMES RESEARCH
W6: EXPERT OPINION AND COUNTRY SEPCIFIC MODEL ADAPTATIONS Skylark
Discussion Leaders: Bruce Crawford MA, MPH, General Manager, Asia, Mapi Values, Tokyo, Meguro, Japan; Chris Evans PhD, MPH, Director of Economics and Outcomes, Mapi Values, Boston, MA, USA.
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W7: PHARMACOECONOMIC GUIDELINES IN CHINA AND THAILAND Flamingo (Speakers at this workshop were invited)
Application of Pharmacoeconomics & Outcomes Research in China
Discussion Leader: Ming Tang PhD, Principal Director, Center of Pharmacoeconomic Evaluation,
Chinese Medical Doctor Association, Beijing, China
Development of the National Guidelines for Conducting Pharmacoeconomic Evaluation in Thailand
Discussion Leader: Yot Teerawattananon PhD, Health Intervention and Technology Assessment Program, Ministry of Public Health, Thailand.
W8: HEALTH TECHNOLOGY ASSESSMENT IN ASIAN-PACIFIC COUNTRIES. White Heron
Discussion Leaders: Candace Gunnarsson EdD, President CEO, S2 Statistical Solutions, Inc, Cincinnati, OH, USA; Susan Ross MD, Consultant, SDRoss Consulting, Cohasset, MA, USA; Harry J. Kotlarz MBA, BS, Director, Health Economics and Reimbursement, DePuy Orthopaedics Inc, Warsaw, IN, USA.
PATIENT-REPORTED OUTCOMES
W9: THE ROLE OF UTILITIES IN SUPPORTING MARKET ACCESS IN ASIA: LESSONS LEARNT FROM NICE & CDR Swan
Discussion Leaders: Andrew Lloyd BSc, DrPH, Director, Oxford Outcomes, Oxford, United Kingdom; Nan Luo PhD, Research Fellow, National University of Singapore, Centre for Health Services Research, Singapore, Singapore; Paul Quarterman MSc, Director, Oxford Outcomes, Oxford, Oxon, UK.
USE OF REAL WORLD DATA
W10: THE USE OF REAL WORLD DATA TO ASSESS COMPLIANCE AND ECONOMICS IN HYPERTENSION Crane
Discussion Leaders: Diana Brixner RPh, PhD, Associate Professor, The University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA; Joseph Biskupiak PhD, MBA, Research Associate Professor, University of Utah, College of Pharmacy, Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, Salt Lake City, UT, USA; Gary M Oderda PharmD, MPH, Professor, University of Utah, Department of Pharmacotherapy, Salt Lake City, UT, USA; Abdulkadir Keskinaslan MD, MBA, MPH, HE Manager, Novartis Pharma AG, Global HE & OR CVM, Basel, Switzerland. |
2:30PM-2:45PM |
BREAK, EXHIBITS AND POSTER
PRESENTATIONS VIEWING Grand Ballroom |
|
|
2:45PM-3:45PM |
PODIUM PRESENTATIONS-SESSION III |
|
Cancer Flamingo |
| Moderator: Tini Q. Chau Nguyen PharmD, HE Dipl., Director, Health Outcomes & Market Access, Asia Pacific, Sanofi-Aventis, Paris, France |
| |
|
| CN1: |
THE IMPACT OF SUSPECTED SUPERFICIAL BLADDER CANCER ON HEALTHCARE RESOURCE UTILIZATION: A KOREAN PERSPECTIVE |
| |
Barwell AC1, Zyczynski T2, Hong SJ3
1Abacus International, Bicester, Oxon, United Kingdom, 2GE Healthcare, Princeton, NJ, USA, 3Severance Hospital, Seoul, South Korea |
| |
|
| CN2: |
COST-MINIMIZATION ANALYSIS OF CAPECITABINE FOR ADVANCED GASTRIC CANCER IN TAIWAN |
| |
Chao Y1, Chang CS2, Chen JS3, Chen LT4, Chung CH5, Hsieh RK6, Hwang WS7, Yang L8, De Reyder F9
1Taipei Veterans General Hospital, Taipei, Taiwan, 2Changhua Christian Memorial Hospital, Changhua, Taiwan, 3Chang Gung Memorial Hospital, LinKou, Taiwan, 4National Health Research Institutes, Taipei, Taiwan, 5Kaoshiung Medical University Hospital, Kaoshiung, Taiwan, 6 Mackay Memorial Hospital, Taipei, Taiwan, 7Chi Mei Medical Center, Tainan, Taiwan, 8Roche Products Ltd, Taipei, Taiwan, 9F. Hoffmann-La Roche AG, Basel, Switzerland |
| |
|
| CN3: |
COST EFFECTIVENESS OF CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER |
| |
Lim S1, Lim G2, Goh A3
1Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, 2Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, 3ClinResearch Sdn Bhd, Kuala Lumpur, Malaysia |
| |
|
| CN4: |
IMATINIB IS COST-EFFECTIVE THAN INTERFERON-ALPHA (IFN) FOR PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA FROM THE CHINESE PUBLIC HEALTHCARE SYSTEM PERSPECTIVE |
| |
Wang C1, Chen Z2, Feng W3
1Shanghai Jiaotong University Affiliated First Hospital, Shanghai, Shanghai, China, 2Shanghai Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China, 3Novartis Pharmaceuticals, Florham Park, NJ, USA |
| |
|
| Cardiovascular Disease Skylark |
| Moderator: Xin (Sam) Ye MS, PhD, Associate Director, i3 Innovus, An Ingenix Company, Eden Prairie, MN, USA |
| |
|
| CV1: |
TO COMPARE THE THERMAL RESPONSE OF NIFEDIPINE WITH GINKGO IN PATIENTS WITH RAYNAUD'S DISEASE BY DIGITAL INFRARED THERMOGRAPHIC IMAGING ; KOREAN RAYNAUD DITI STUDY |
| |
Choi WS1, Kim SH1, Ju SY1, Chung JH1, Lee JB2, Kim CM1
1Catholic University, Seoul, South Korea, 2Korea University, Ansan, South Korea |
| |
|
| CV2: |
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF STATINS ON REDUCING ACUTE CORONARY SYNDROME AND STROKE EVENTS |
| |
Tamteeranon Y1, Chaikledkaew U1, Khonputsa P2, Teerawattananon Y1
1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2Setting Priority using Information on Cost-Effectiveness (SPICE), Nonthaburi, Thailand |
| |
|
| CV3: |
UTILIZATION OF NEW DRUG AND MEDICAL EXPENDITURE OF HYPERTENSION PATIENTS: EMPIRICAL EVIDENCE FROM ANGIOTENSIN II RECEPTOR BLOCKERS IN TAIWAN |
| |
Liu YM, Kao Yang YH, Chang CY
1National Cheng Kung University, Tainan, Taiwan |
| |
|
| CV4: |
THE CLINICAL AND ECONOMIC BENEFIT OF CHANGING THE NATIONAL REIMBURSEMENT CRITERIA FOR CHOLESTEROL LOWERING DRUG THERAPY IN KOREA |
| |
Kang HY1, Liew D2, Ko S3, Kim J4
1Yonsei University, Seoul, South Korea, 2University of Melbourne, Melbourne, Victoria, Australia, 3Pfizer Korea, Seoul, South Korea, 4Konyang University, Chungnam, South Korea |
| |
|
Diabetes White Heron |
| Moderator: Kenneth KC Lee JP, BSc(Pharm), MPhil, PhD, Professor & Associate Director (External Affairs), School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China |
| |
|
| DB1: |
RISK FACTORS FOR AND INCIDENCE RATE OF TYPE 2 DIABETES RELATED HOSPITALIZATION USING CLAIMS DATA IN SOUTH KOREA |
| |
Kim CM1, Choi IS2, Jang SM3, Gerth W4, Suh DC2, Choi WS1
1Catholic University, Seoul, Suhcho-gu, South Korea, 2Rutgers University, Piscataway, NJ, USA, 3Health Insurance Review Agency, Seoul, South Korea, 4Merck & Co., Inc, Whitehouse Station, NJ, USA |
| |
|
| DB2: |
A SURVEY OF DIABETES KNOWLEDGE AMONG THE GENERAL POPULATION IN THAILAND |
| |
Pongmesa T1, Wee HL1, Li SC2
1National University of Singapore, Singapore, Singapore, 2University of Newcastle, Callaghan, NSW, Australia |
| |
|
| DB3: |
ACARBOSE IN ADDITION TO EXISTING TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES: HEALTH ECONOMIC ANALYSES IN A CHINESE SETTING |
| |
Chen X1, Clegg JP2, Chen L1, Yu H3, Wittrup-Jensen KU4, Valentine WJ2
1Fu Dan University, Shanghai, China, 2IMS Health, Basel, Switzerland, 3Bayer Healthcare Co. Ltd, Shanghai, China, 4Bayer Schering Pharma AG, Berlin, Germany |
| |
|
| DB4: |
MODELLING THE COST-EFFECTIVENESS OF ACARBOSE IN PREVENTING TYPE 2 DIABETES IN A SOUTH KOREAN SETTING |
| |
JongMann K1, Clegg JP2, Chang K1, JuYeol P1, Wittrup-Jensen KU3, Palmer AJ4, Roze S4, Valentine WJ5
1Bayer, Seoul, South Korea, 2IMS, Allschwil, Switzerland, 3Bayer Schering Pharma AG, Berlin, Germany, 4CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 5IMS Health, Basel, Switzerland |
| |
|
| Infection Swan |
| Moderator: Jens Grueger PhD, Novartis Pharma AG, Global Marketing & Sales, Head Global Pricing & Reimbursement, Basel, Switzerland |
| |
|
| IF1: |
EFFECTIVENESS AND SAFETY OF COMBINATION THERAPY OF ZIDOVUDINE AND LAMIVUDINE FOR PREVENTING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV: A SYSTEMATIC REVIEW |
| |
Wang L1, Li Y2, Sun X2, Peng L1
1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, China |
| |
|
| IF2: |
AN ECONOMIC EVALUATION OF ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS IN KOREA |
| |
Jo C1, Kim SI2, Jun S3
1Hallym University, Chuncheon, South Korea, 2Catholic University, Seoul, South Korea, 3Korea Institute of Environment and Health, Seoul, South Korea |
| |
|
| IF3: |
THE QUALITY OF SYSTEMATIC REVIEWS OR META-ANALYSES ON PERINATAL ANTIRETROVIRAL THERAPIES FOR PREVENTING MOTHER-TO-CHILD TRANSMISSION OF HIV |
| |
Wang L1, Peng L1, Sun X2, Li Y2
1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, China |
| |
|
| IF4: |
A HEALTH ECONOMICS MODEL TO ESTIMATE THE COST DIFFERENCE BETWEEN STOCKPILING VERSUS NOT STOCKPILING PRE-PANDEMIC INFLUENZA VACCINE |
| |
Tucker D1, Williams P2, Standaert BA3 |
| |
1GlaxoSmithKline Biologicals, Wavre, Belgium, 2Navitas BioPharma Consulting, Buckinghamshire, United Kingdom, 3GlaxoSmithKline Biologicals, Rixensart, Belgium |
| Mental Health Crane |
| Moderator: Guk-Hee Suh MD, PhD, Professor of Psychiatry, Hallym University Medical Center, Hangang Sacred Heart Hospital, Seoul, Korea |
| |
|
| MH1: |
PATIENT AND PHYSICIAN SATISFACTION WITH RISPERIDONE LONG-ACTING INJECTION: INTERIM RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN KOREA |
| |
Lee MS1, Kim YS2, Lee DG3, Paik IH4, Lee HK4, Jung IK1, Lee JG5, Hah TM6, Zhao Z7
1Korea University, Seoul, South Korea, 2Seoul National University, Seoul, South Korea, 3Goyang Mental Hospital, Goyang, South Korea, 4The Catholic University of Korea, Seoul, South Korea, 5Masan Dongsuh Hospital, Masan, South Korea, 6Busan Dongrae Hospital, Busan, South Korea, 7JJPS, Raritan, NJ, USA |
| |
|
| MH2: |
HOSPITALIZATION ASSOCIATED WITH RISPERIDONE LONG ACTING INJECTION TREATMENT IN SCHIZOPHRENIA: 6-MONTH RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN KOREA |
| |
Kim YS1, Lee MS2, Lee DG3, Paik IH4, Lee HK4, Jung IK2, Lee JG5, Hah TM6, Zhao Z7
1Seoul National University, Seoul, South Korea, 2Korea University, Seoul, South Korea, 3Goyang Mental Hospital, Goyang, South Korea, 4The Catholic University of Korea, Seoul, South Korea, 5Masan Dongsuh Hospital, Masan, South Korea, 6Busan Dongrae Hospital, Busan, South Korea, 7JJPS, Raritan, NJ, USA |
| |
|
| MH3: |
ECONOMIC EVALUATION OF PALIPERIDONE ER IN THE TREATMENT OF SCHIZOPHRENIA PATIENTS IN TAIWAN |
| |
Yang YK1, Liu CY2, Pwu RF3, Ko SY4, Tsai IC4
1National Cheng Kung University, Tainan, Taiwan, 2Chang Gung Memorial Hospital, Tao Yuan, Taiwan, 3Taipei Medical University, Taipei, Taiwan, 4Janssen Cilag Taiwan, Taipei, Taiwan |
| |
|
| MF4: |
RISPERIDONE LONG ACTING INJECTION TREATMENT IN SCHIZOPHRENIA: 6-MONTH RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN KOREA |
| |
Lee MS1, Kim YS2, Lee DG3, Paik IH4, Lee HK4, Jung IK1, Lee JG5, Hah TM6, Zhao Z7
1Korea University, Seoul, South Korea, 2Seoul National University, Seoul, South Korea, 3Goyang Mental Hospital, Goyang, South Korea, 4The Catholic University of Korea, Seoul, South Korea, 5Masan Dongsuh Hospital, Masan, South Korea, 6Busan Dongrae Hospital, Busan, South Korea, 7JJPS, Raritan, NJ, USA |
| |
|
|
3:45PM-4:00PM |
BREAK, EXHIBITS & POSTER
PRESENTATIONS VIEWING Grand Ballroom |
|
|
4:00PM-5:00PM |
|
|
CLINICAL OUTCOMES RESEARCH
W11: WEB-BASED SYSTEMATIC REVIEWS – A NEW TOOL FOR AN EVOLVING PROCESS White Heron
Discussion Leaders: Peter O'Blenis BCS, MBA, Vice-President, Product Development, TrialStat Corporation, Ottawa, ON, Canada.
ECONOMIC OUTCOMES RESEARCH
W12: IS ONE-PART MODEL ENOUGH FOR ANALYZING HEALTH CARE COST DATA? Skylark
Discussion Leaders: Xin (Sam) Ye MS, PhD, Associate Director¹; Henry Joe Henk PhD, Director¹.
¹i3 Innovus, An Ingenix Company, Eden Prairie,
MN, USA.
PATIENT-REPORTED OUTCOMES
W14: WILLINGNESS TO PAY FOR A QALY IN EAST ASIA Swan
Discussion Leaders: Kiichiro Tsutani MD, PhD, Professor, The University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan; Takashi Fukuda PhD, Associate Professor, The University of Tokyo, School of Public Health, Tokyo, Japan; Sang-Cheol Bae MD, PhD, MPH, Professor, Hanyang University College of Medicine, Seoul, South Korea; Hui-Chu Lang PhD, Associate Professor, National Yang-Ming University, Institute of Hospital and Health Care Administration, Taipei, Taiwan.
USE OF REAL WORLD DATA
W15: PAYING FOR PILLS BY RESULTS: PERFORMANCE-BASED REWARDS FOR INNOVATION AND THEIR IMPLICATIONS FOR THE ASIA PACIFIC REGION Flamingo
Discussion Leaders: Lou Garrison PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Dept of Pharmacy, Seattle, WA, USA; Sean D. Sullivan PhD, Professor, University of Washington, Department of Pharmacy, Seattle, WA, USA; Adrian Towse MPhil, Director, Office of Health Economics, London, UK. |
5:00PM-5:15PM |
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING Grand Ballroom |
|
|
| 5:15PM-6:00PM |
ISPOR RESEARCH AWARDS PRESENTATION;
ISPOR 4th ASIA-PACIFIC CONFERENCE
ANNOUNCEMENT; CLOSING REMARKS Convention Hall DE |
|
ISPOR RESEARCH AWARDS PRESENTATION
Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea
ISPOR 4th ASIA-PACIFIC CONFERENCE ANNOUNCEMENT
Surachat Ngorsuraches PhD. RPh, Co-Chair, ISPOR 4th Asia-Pacific Conference, and Head of Pharmacy Administration Department, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkla, Thailand
Vithaya Kulsomboon PhD, Co-Chair, ISPOR 4th Asia-Pacific Conference, President, ISPOR Thailand Chapter, Associate Professor & Chair of Social Pharmacy Department, and Director of Graduate Program in Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Patumwan, Bangkok, Thailand
CLOSING REMARKS
Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea |
| |
|
|
|
